The Division of Medical Oncology faculty are dedicated to the creation of a cancer-free world through our efforts in research, clinical care, education, and philanthropy. Faculty research is conducted as an integrated effort within The Ohio State University Comprehensive Cancer Center, one of 40 such centers in the United States designated by the National Cancer Institute. Our research spans the spectrum of basic laboratory science, clinical investigation, and population science.

The Division of Medical Oncology program takes particular pride in our commitment to translational research investigations that involve both clinical and basic scientists in directly transforming their to our patients through interdisciplinary disease centers, each directed by nationally recognized leaders whom are responsible for orchestrating the clinical care and research.

Our established disease centers include those focusing upon breast cancer, gastrointestinal cancers, genitourinary cancers, sarcomas, lung cancers, head and neck cancers and endocrine cancers. Our efforts are enhanced by National Cancer Institute support for Phase I and Phase II clinical trials, allowing us to bring the latest in novel therapies to patients at the Arthur G. James Cancer Hospital and Solove Research Institute. Access to new trials is further enhanced through our membership in the cooperative group, Cancer and Leukemia Group B (CALGB), a national network of 26 university medical centers that collaborate on large scale clinical studies.

Our reputation for excellence in cancer research serves as a magnet for recruitment of the best young investigators to our faculty, fellows in training, and outstanding nursing staff to serve our patients with exceptional medical care at the Arthur G. James Cancer Hospital and Solove Research Institute. Although our faculty and staff are distinguished by their commitment to research while providing our patients with access to the latest treatment advances, our team is equally committed to excellence in compassionate cancer care.


Clinical Trials

Featured Trials


Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer
(OSU-15281) Robert Wesolowski, MD


Recently Opened Trials



Gastrointestinal


Phase I/II, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies
(OSU-15241) Kristen Ciombor, MD

Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
(ALLIANCE-A021501) Terence Williams, MD, PhD

Genitourinary

Randomized Phase II Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial Carcinoma
(OSU-17029) Amir Mortazavi, MD

Head and Neck


Open-Label, Multicenter Phase I/II Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
(OSU-16147) Maura Gillison, MD, PhD

Melanoma


Randomized, Controlled, Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
(OSU-16073) Harrison Howard, MD

Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
(OSU-14129) Thomas Olencki, DO

Thoracic


Phase Ib Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
(OSU-16155) Erin Bertino, MD


Immune Therapy Trials



Breast


Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With Her2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane-Based Therapy
(OSU-16193) Robert Wesolowski, MD

Gastrointestinal


Phase I, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
(OSU-15169) Kristen Ciombor, MD

Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
(OSU-15298) Richard Goldberg, MD

Phase I, Open-Label, Multiple-Ascending-Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
(OSU-13257) John Hays, MD, PhD

Genitourinary


Phase I, Multiple-Dose, Dose-Escalation Trial of Pt2385 Tablets, a HIF-2alpha Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
(OSU-16236) J. Paul Monk, III, MD

Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti−Pd-L1 Antibody) vs. Observation as Adjuvant Therapy in Patients With Pd-L1−Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy
(OSU-16078) Amir Mortazavi, MD

Phase I Study of (Cabozantinib) Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
(OSU-15150) Amir Mortazavi, MD

Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab vs. Placebo After First-line Chemotherapy in Patients With Metastatic Urothelial Cancer
(OSU-16133) Amir Mortazavi, MD

Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
(OSU-14248) Thomas Olencki, DO

Phase III, Multinational, Randomized, Open-label, Parallel-Arm Study of Avelumab (Msb0010718c) in Combination With Axitinib (Inlyta®) vs. Sunitinib (Sutent®) Monotherapy in the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
(OSU-15292) Thomas Olencki, DO

Gynecologic


Phase I/II Study of Chemo-Immunotherapy With Toll-Like Receptor 8 Agonist Motolimod (VTX-2337) and Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated
(OSU-15125) David O’Malley, MD

Phase I/IIa Dose-Escalation and Cohort Expansion Study for Safety, Tolerability and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors
(OSU-16195) David O’Malley, MD

Melanoma


Randomized, Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
(ECOG-EA6134) Joanne Jeter, MD

Phase I/II Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification
(OSU-15280) Joanne Jeter, MD

Phase II and Pilot Trial of PD-1 Blockade With MK-3475 (Pembrolizumab) in Patients With Resectable or Unsectable Desmoplastic Melanoma (DM)
(SWOG-S1512) Kari Kendra, MD, PhD

Neuroendocrine


Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
(OSU-15244) Manisha Shah, MD

Thoracic


Phase Ib Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan-High Solid Tumors
(OSU-15219) Erin Bertino, MD

Phase I/Ib, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab Therapy in Patients With Selected Incurable Cancers
(OSU-16051) Erin Bertino, MD

Phase II Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)
(OSU-16136) Kai He, MD, PhD

Phase II, Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
(OSU-16120) Kai He, MD, PhD

Phase I, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel/Carboplatin in Stage IIIb/IV Non-Small Cell Lung Cancer or Nab- Paclitaxel in Recurrent Metastatic Breast Cancer
(OSU-14250) Greg Otterson, MD

Randomized, Multicenter, Double-Blind, Phase III Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-Based First-Line Chemotherapy
(OSU-15171) Greg Otterson, MD

Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer
(OSU-16074) Greg Otterson, MD

Open-Label, Multicenter, Phase I/II Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
(OSU-16147) Greg Otterson, MD

Contact the Division

A455A Starling-Loving Hall
320 West 10th Avenue
Columbus, OH 43210

Division Administrator:
Katie Barnes


Phone: 614-366-3505
Fax: 614-293-7520
Email

Assistant to Division Director:
Robby W. Stephens


Phone: 614-366-5068
Email

Fiscal Officer:
Kristina Ambrosio


Phone: 614-293-5484
Email

Search for Clinical Trials